Fig. 1 · Structure

Documents & Downloads

R306465

Cat. No. A15437 CAS 604769-01-9

HDAC inhibitor

R306465 is a novel hydroxamate-based histone deacetylase (HDAC) inhibitor with broad-spectrum antitumour activity against solid and haematological malignancies in preclinical models.

In Stock

Publications for R306465

1 publication citing this product

  1. Mari Ishigami-Yuasa, .et al. , Biol Pharm Bull, 2019, 42, 448-452 PMID: 30828077

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

R306465 inhibited A2780-derived HDAC1 complexes and recombinant HDAC8, with reported IC50 values of 3.31±0.78 nM and 23±17 nM, respectively. These are assay-specific biochemical endpoints. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

R306465 Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of R306465 from 1 published reference.

R306465 In Vitro Studies

R306465 inhibited A2780 proliferation (IC50 39±17 nM). Proliferating normal mammary epithelial cells were similarly sensitive (32±9.7 nM); quiescent cells had a reported IC50 of 7815±435 nM. These findings do not establish tumor-specific activity. [1]

HDAC1 and HDAC8 inhibition

Biochemical assay · A2780-derived immunoprecipitated HDAC1 complexes and recombinant human HDAC8 [1]

Assay-specific enzyme inhibition; these IC50 values are not cellular treatment concentrations.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of HDAC1-complex deacetylase activityIC50 3.31±0.78 nM[1]
Inhibition of recombinant human HDAC8 activityIC50 23±17 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Increasing inhibitor concentrations; exact range not specified in the selected assay methods.
Exposure duration
HDAC1: 10-min inhibitor preincubation, followed by 45-min reaction.
Method
Biochemical enzyme activity assays; panobinostat, vorinostat, MS-275 and TSA comparator values are presented in Table 1.
Vehicle
DMSO stocks; final assay DMSO fraction not specified.
Reported limits
HDAC8 incubation duration and explicit zero-inhibitor well composition are not specified in the retrieved assay description.
Methods and source locations

Compound reported in the paper: R306465; Compound label in the paper: JNJ-16241199

Evidence concerns the reported research material; no Adooq lot equivalence is established.

Table 1 and footnote; Materials and methods: Compounds and Histone deacetylase activity assays; Figure 1

Inhibition of HDAC1-complex deacetylase activity: Radiolabeled acetyl-H4 peptide substrate; mean±s.d., three independent experiments on one lysate. — Table 1, R306465 row, HDAC1-IP Ac-H4 column; Histone deacetylase activity assays

Inhibition of recombinant human HDAC8 activity: Commercial HDAC8 colorimetric/fluorimetric assay; Table 1 describes mean±s.d. for three independent experiments. — Table 1, R306465 row, HDAC8 column and footnote

Tumor-cell and normal-cell proliferation

Cell-based study · Human A2780 ovarian carcinoma cells and primary human mammary epithelial cells (HMEC) [1]

A2780 proliferation was inhibited, but proliferating HMEC were similarly sensitive. Quiescent HMEC were less sensitive. The HMEC values are reported in the Results text as data not shown.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
A2780 cell proliferationIC50 39±17 nM[1]
Proliferating HMEC cell proliferationIC50 32±9.7 nM[1]
Quiescent, non-proliferative HMEC responseIC50 7815±435 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response assays; IC50 endpoints are reported separately.
Exposure duration
4 days for the standard solid-cell MTT assay.
Method
MTT-based assessment; Figure 3 presents a broader cell panel, but individual curve values were not digitized.
Vehicle
DMSO ≤0.1% (v/v) in proliferation assays.
Reported limits
HMEC quiescence protocol and HMEC-specific control data are not shown. No cancer-selective toxicity inference is supported.
Methods and source locations

Compound reported in the paper: R306465; Compound label in the paper: JNJ-16241199

Evidence concerns the reported research material; no Adooq lot equivalence is established.

Table 1; Figure 3 and caption; Results: broad-spectrum antiproliferative activity, HMEC paragraph; Cell-proliferation assays

A2780 cell proliferation: Four-day MTT assay; mean±s.d., three independent experiments. — Table 1, A2780 proliferation column and footnote; Cell-proliferation assays

Proliferating HMEC cell proliferation: Reported in Results; common proliferation methods describe MTT and mean±s.d. of three independent experiments. HMEC-specific underlying data are not shown. — Results: R306465 has broad-spectrum antiproliferative activity, HMEC paragraph

Quiescent, non-proliferative HMEC response: Reported IC50 in Results; data not shown. The method of inducing quiescence is not specified in the retrieved text. — Results: R306465 has broad-spectrum antiproliferative activity, HMEC paragraph

R306465 In Vivo Studies

In an early-treatment A2780 xenograft model, once-daily oral R306465 reduced final median tumor volume relative to vehicle. T/C values were 47%, 13% and 24% at 10, 20 and 40 mg/kg, respectively (n=10 per group), so this endpoint was not strictly dose-monotonic. [1]

Oral R306465 in the A2780 xenograft model

Animal study · Male athymic NMRI nu/nu mice bearing subcutaneous A2780 ovarian carcinoma xenografts [1]

Final median tumor size was lower than vehicle at each reported dose. The 20 mg/kg group had a lower final treated/control value than the 40 mg/kg group; the endpoint is not strictly dose-monotonic. No survival endpoint is adopted.

Conditions shared by the study groups

Route
Oral (p.o.)
Frequency
Once daily
Treatment course
Between days 4 and 28, per Figure 7 caption.
Vehicle
20% HP-β-CD
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
10 mg/kg R306465Vehicle control; n=10.Final median tumor-volume treated/control (T/C) value: 47%.[1]
20 mg/kg R306465Vehicle control; n=10.Final median tumor-volume treated/control (T/C) value: 13%.[1]
40 mg/kg R306465Vehicle control; n=10.Final median tumor-volume treated/control (T/C) value: 24%.[1]
10 mg/kg R306465
Model: A2780 subcutaneous xenograft; male athymic NMRI nu/nu mice; n=10 per group.
Reported limits: Exact dose count differs between the general methods wording and Figure 7A timeline. No uncertainty interval or significance test accompanies the tabulated T/C value.
20 mg/kg R306465
Model: A2780 subcutaneous xenograft; male athymic NMRI nu/nu mice; n=10 per group.
Reported limits: Exact dose count differs between the general methods wording and Figure 7A timeline. No uncertainty interval or significance test accompanies the tabulated T/C value.
40 mg/kg R306465
Model: A2780 subcutaneous xenograft; male athymic NMRI nu/nu mice; n=10 per group.
Reported limits: Exact dose count differs between the general methods wording and Figure 7A timeline. No uncertainty interval or significance test accompanies the tabulated T/C value.
Methods and source locations

Compound reported in the paper: R306465; Compound label in the paper: JNJ-16241199

Evidence concerns the reported research material; no Adooq lot equivalence is established.

Figure 7A/B and caption; Results: inhibits tumour growth in vivo; Materials and methods: In vivo antitumoral studies

10 mg/kg R306465 · Figure 7B, A2780 column, 10 mpk row; Figure 7 caption

20 mg/kg R306465 · Figure 7B, A2780 column, 20 mpk row; Figure 7 caption

40 mg/kg R306465 · Figure 7B, A2780 column, 40 mpk row; Figure 7 caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 604769-01-9
Applications HDAC inhibitor
Formula C19H19N5O4S
Molecular Weight 413.45
Synonyms JNJ-16241199
SMILES
C1CN(CCN1C2=NC=C(C=N2)C(=O)NO)S(=O)(=O)C3=CC4=CC=CC=C4C=C3

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

R306465 Research References

  1. [1] Arts J, Angibaud P, Mariën A, et al. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies British Journal of Cancer (2007). PMID: 18000499 DOI: 10.1038/sj.bjc.6604025 Source material

Publications

1 publication citing this product

  1. Mari Ishigami-Yuasa, .et al. , Biol Pharm Bull, 2019, 42, 448-452 PMID: 30828077

Added to your cart

View Cart Checkout
Loading...